Intervention Insights Publishes Conference Report: "Personalized Medicine-Promises and Perils for Community Oncology and Payers"
Grand Rapids, MI, June 22, 2011 --(PR.com)-- Intervention Insights, Inc., a company that offers a personalized medicine (PM) service for oncologists, released a report summarizing the workshops, presentations and survey results from its inaugural conference, Personalized Medicine: Promises and Perils for Community Oncology and Payers.
This one-and-a-half day gathering in Grand Rapids, Michigan represented a first-of-its-kind opportunity for oncologists and regional payer representatives to discuss the issues surrounding the adoption of personalized medicine in the community setting.
“Academic medical centers have been leading the effort to bring the latest molecular information to bear on treatment decisions for oncology patients, while these services have not been as readily available in our communities,” said Jerry Callahan, PhD., CEO at Intervention Insights. “We wanted to address this gap by bringing together 2 key stakeholders in the practice of community oncology.”
The report includes results of a survey designed to gauge attendee mindsets with regard to the current state and future of personalized medicine. For example:
• 94% either somewhat agree or disagree that most practicing oncologists have a firm grasp of currently available molecular tests.
• 88% either disagree of strongly disagree that existing resources provide adequate information on available molecular tests.
• 70% either agree or strongly agree that becoming an early adopter of personalized medicine is essential for the success of their organization or practice.
• 75% either agree or strongly agree that all patients will eventually benefit from a molecularly driven personalized approach to their care.
Other report highlights include a summary of interactive workshops in which the drivers and obstacles to the adoption of PM were established. For instance, almost all participants were aligned in the belief that the promise of improved patient outcomes will drive the adoption of PM. Economics were deemed another major driver, with the rapid emergence of molecularly targeted—and costly—therapies demanding a means of determining a patient’s likelihood of response or failure. However, physicians and payers noted a lack of decision support tools at the point-of-care in the community setting to guide molecularly driven treatment decisions.
Other discussions centered on questions of cost effectiveness when applying personalized medicine services to large populations, a particular concern for payers, and on defining a regulatory path to clinical acceptance, requiring an alignment of multiple stakeholders.
Attendee and presenter, Dr. John Fox, Senior Medical Director Priority Health, noted: “This conference provided a unique opportunity for regional payers to sit in the same room with oncologists and engage in an open dialog on the evidence needed to permit adoption of personalized medicine services.”
The 7-page report is available for download at:
http://www.interventioninsights.com
About Intervention Insights
Launched in 2009 in Grand Rapids, Michigan, Intervention Insights was formed to provide community oncologists with information to support their selection of the right drug at the right time for their patients. The company is constantly expanding and refining its knowledge base on the molecular mechanisms of cancer and drug response to support community oncologists in developing molecularly-driven treatment strategies tailored to the individual. Our mission is to improve the lives of patients afflicted with cancer by empowering community oncologists with evidence-based treatment interventions.
###
This one-and-a-half day gathering in Grand Rapids, Michigan represented a first-of-its-kind opportunity for oncologists and regional payer representatives to discuss the issues surrounding the adoption of personalized medicine in the community setting.
“Academic medical centers have been leading the effort to bring the latest molecular information to bear on treatment decisions for oncology patients, while these services have not been as readily available in our communities,” said Jerry Callahan, PhD., CEO at Intervention Insights. “We wanted to address this gap by bringing together 2 key stakeholders in the practice of community oncology.”
The report includes results of a survey designed to gauge attendee mindsets with regard to the current state and future of personalized medicine. For example:
• 94% either somewhat agree or disagree that most practicing oncologists have a firm grasp of currently available molecular tests.
• 88% either disagree of strongly disagree that existing resources provide adequate information on available molecular tests.
• 70% either agree or strongly agree that becoming an early adopter of personalized medicine is essential for the success of their organization or practice.
• 75% either agree or strongly agree that all patients will eventually benefit from a molecularly driven personalized approach to their care.
Other report highlights include a summary of interactive workshops in which the drivers and obstacles to the adoption of PM were established. For instance, almost all participants were aligned in the belief that the promise of improved patient outcomes will drive the adoption of PM. Economics were deemed another major driver, with the rapid emergence of molecularly targeted—and costly—therapies demanding a means of determining a patient’s likelihood of response or failure. However, physicians and payers noted a lack of decision support tools at the point-of-care in the community setting to guide molecularly driven treatment decisions.
Other discussions centered on questions of cost effectiveness when applying personalized medicine services to large populations, a particular concern for payers, and on defining a regulatory path to clinical acceptance, requiring an alignment of multiple stakeholders.
Attendee and presenter, Dr. John Fox, Senior Medical Director Priority Health, noted: “This conference provided a unique opportunity for regional payers to sit in the same room with oncologists and engage in an open dialog on the evidence needed to permit adoption of personalized medicine services.”
The 7-page report is available for download at:
http://www.interventioninsights.com
About Intervention Insights
Launched in 2009 in Grand Rapids, Michigan, Intervention Insights was formed to provide community oncologists with information to support their selection of the right drug at the right time for their patients. The company is constantly expanding and refining its knowledge base on the molecular mechanisms of cancer and drug response to support community oncologists in developing molecularly-driven treatment strategies tailored to the individual. Our mission is to improve the lives of patients afflicted with cancer by empowering community oncologists with evidence-based treatment interventions.
###
Contact
Intervention Insights
Dennis Zoet
(616) 949-7500
www.interventioninsights.com
Dennis Zoet
(616) 949-7500
www.interventioninsights.com
Contact
Categories